MedTrace Logo

Vogelxo(R) ABPM Study in Hypogandal Men

NCT04558567 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 122

Last updated 2024-10-18

No results posted yet for this study

Summary

A Phase 4 ABPM study in Hypogonadal Men

Conditions

  • Hypogonadism, Male

Interventions

DRUG

Vogelxo

50mg (1 tube, 5g gel) to 100mg (2 tubes, 10g gel)

Sponsors & Collaborators

  • Upsher-Smith Laboratories

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-28
Primary Completion
2023-12-12
Completion
2024-01-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04558567 on ClinicalTrials.gov